Petrovic Shacey 4

What Happened

• Shacey Petrovic, a director of Exact Sciences Corporation (EXAS), had a total of 28,899 shares disposed on March 23, 2026 via dispositions to the issuer in connection with the company’s merger with Abbott. The merger converted each share of EXAS common stock into $105.00 in cash, so the converted shares correspond to approximately $3,034,395 in aggregate consideration.
• These were not open-market sales but conversions of outstanding shares (including vested/restricted shares) into cash under the Merger Agreement.

Key Details

• Transaction date: March 23, 2026 (Effective Time of the merger).
• Shares disposed: 16,406 + 5,398 + 7,095 = 28,899 shares.
• Per-share consideration: $105.00; aggregate ≈ $3,034,395.
• Disposition type: "D" — disposition to the issuer pursuant to the Merger Agreement (not an open-market sale).
• Footnotes: Under the Merger Agreement (dated Nov 19, 2025), each outstanding share (with certain exceptions) was converted into $105 cash (F1). Shares subject to vesting/repurchase restrictions were deemed fully vested, cancelled, and converted into cash less any applicable tax withholding (F2).
• Shares owned after the transaction: the Form 4 reports these dispositions as conversion into cash; the filing does not list remaining EXAS common shares post-merger for these lots.
• Filing timeliness: Reported on March 23, 2026 (same date as the Effective Time), indicating a timely post-merger filing.

Context

• These transactions reflect merger consideration paid by Abbott upon its acquisition of Exact Sciences, not discretionary insider selling. Conversions of restricted/vested shares into cash upon a takeover are routine and are driven by transaction terms rather than an insider trading decision.
• Retail investors should view this as a corporate liquidity event (cash-out) rather than a signal of insider sentiment about the company's future stock performance.